Leidos <LDOS.N>: Citigroup raises target price to $161 from $138
LDOS•Related News
AC Immune wins FDA fast-track status for Parkinson’s immunotherapy ACI-7104
ACIU•
Tenax Therapeutics Inc <TENX.O>: William Blair cuts to market perform rating
TENX•
Green Thumb subsidiaries RSLGH, VMS amend RYTHM warrants, notes to lift beneficial ownership limits
GTBIF•
Tango Therapeutics Q2 net loss widens as expenses rise
TNGX•
Xtant Medical Q2 FY26 turns to net loss of $9.41 million; revenue drops 34.96% to $23.03 million
XTNT•